[
  {
    "id": "pfizer",
    "name": "Pfizer",
    "description": "Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered in New York City. It is one of the world's largest pharmaceutical companies, focusing on research, development, and manufacturing of medicines and vaccines for a wide range of medical disciplines.",
    "logoUrl": "/src/data/assets/logos/pfizer.svg",
    "headerImageUrl": "/images/headers/pfizer-header.jpg",
    "headquarters": "New York, USA",
    "founded": "1849",
    "website": "pfizer.com",
    "marketCap": 240.5,
    "employees": 79000,
    "stockSymbol": "PFE",
    "stockExchange": "NYSE",
    "therapeuticAreas": [
      "oncology",
      "vaccines",
      "immunology",
      "rare-diseases",
      "inflammation",
      "cardiovascular"
    ],
    "products": [
      {
        "id": "exampla",
        "name": "Exampla",
        "description": "A monoclonal antibody targeting inflammatory pathways.",
        "status": "marketed",
        "approvalDate": "2018-06-15",
        "therapeuticAreas": ["immunology", "dermatology"]
      },
      {
        "id": "cardiofix",
        "name": "CardioFix",
        "description": "A dual-action therapy for cardiovascular disease management.",
        "status": "phase3",
        "therapeuticAreas": ["cardiovascular"]
      },
      {
        "id": "oncovax",
        "name": "OncoVax",
        "description": "Revolutionary oncology vaccine for prevention of recurrence.",
        "status": "phase2",
        "therapeuticAreas": ["oncology"]
      }
    ],
    "relatedCompanies": [
      {
        "id": "novartis",
        "relationship": "competitor"
      },
      {
        "id": "astrazeneca",
        "relationship": "competitor"
      }
    ],
    "milestones": [
      {
        "date": "2020-12-11",
        "title": "COVID-19 Vaccine EUA",
        "description": "Received emergency use authorization for COVID-19 mRNA vaccine.",
        "type": "regulatory"
      },
      {
        "date": "2019-07-29",
        "title": "Upjohn - Mylan Merger",
        "description": "Announced merger of Upjohn division with Mylan to form Viatris.",
        "type": "spinoff"
      },
      {
        "date": "2016-09-28",
        "title": "Medivation Acquisition",
        "description": "Completed acquisition of Medivation for $14 billion.",
        "type": "acquisition"
      }
    ],
    "financials": [
      {
        "year": 2023,
        "revenue": 58.5,
        "rAndDSpending": 11.4,
        "netIncome": 14.3
      },
      {
        "year": 2022,
        "revenue": 100.3,
        "rAndDSpending": 11.1,
        "netIncome": 31.4
      },
      {
        "year": 2021,
        "revenue": 81.3,
        "rAndDSpending": 10.5,
        "netIncome": 22.0
      },
      {
        "year": 2020,
        "revenue": 41.9,
        "rAndDSpending": 9.4,
        "netIncome": 9.6
      },
      {
        "year": 2019,
        "revenue": 51.8,
        "rAndDSpending": 8.7,
        "netIncome": 16.3
      }
    ]
  },
  {
    "id": "novartis",
    "name": "Novartis",
    "description": "Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. One of the largest pharmaceutical companies by revenue and market cap, Novartis develops, manufactures, and markets prescription and over-the-counter medications along with other healthcare products.",
    "logoUrl": "/src/data/assets/logos/novartis.svg",
    "headerImageUrl": "/images/headers/novartis-header.jpg",
    "headquarters": "Basel, Switzerland",
    "founded": "1996",
    "website": "novartis.com",
    "marketCap": 180.3,
    "employees": 108000,
    "stockSymbol": "NVS",
    "stockExchange": "NYSE",
    "therapeuticAreas": [
      "oncology",
      "neuroscience",
      "immunology",
      "ophthalmology",
      "cardiovascular"
    ],
    "products": [
      {
        "id": "luxient",
        "name": "Luxient",
        "description": "Advanced targeted therapy for multiple sclerosis.",
        "status": "marketed",
        "approvalDate": "2016-03-22",
        "therapeuticAreas": ["neuroscience"]
      },
      {
        "id": "neurokem",
        "name": "NeuroKem",
        "description": "Novel neuroprotective agent for neurodegenerative disorders.",
        "status": "phase2",
        "therapeuticAreas": ["neuroscience"]
      }
    ],
    "relatedCompanies": [
      {
        "id": "pfizer",
        "relationship": "competitor"
      },
      {
        "id": "astrazeneca",
        "relationship": "partner"
      }
    ],
    "milestones": [
      {
        "date": "2018-04-09",
        "title": "AveXis Acquisition",
        "description": "Acquired AveXis for $8.7 billion, adding gene therapy capabilities.",
        "type": "acquisition"
      },
      {
        "date": "2017-01-27",
        "title": "Kymriah Approval",
        "description": "First CAR-T cell therapy approved for certain types of leukemia.",
        "type": "regulatory"
      },
      {
        "date": "2014-04-22",
        "title": "GSK Oncology Asset Acquisition",
        "description": "Acquired GlaxoSmithKline's oncology products for $16 billion.",
        "type": "acquisition"
      }
    ],
    "financials": [
      {
        "year": 2023,
        "revenue": 45.4,
        "rAndDSpending": 9.8,
        "netIncome": 12.6
      },
      {
        "year": 2022,
        "revenue": 44.3,
        "rAndDSpending": 9.5,
        "netIncome": 11.5
      },
      {
        "year": 2021,
        "revenue": 52.9,
        "rAndDSpending": 9.0,
        "netIncome": 24.0
      },
      {
        "year": 2020,
        "revenue": 48.7,
        "rAndDSpending": 8.5,
        "netIncome": 8.1
      },
      {
        "year": 2019,
        "revenue": 47.5,
        "rAndDSpending": 8.4,
        "netIncome": 7.1
      }
    ]
  },
  {
    "id": "astrazeneca",
    "name": "AstraZeneca",
    "description": "AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with headquarters in Cambridge, England. AstraZeneca has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory.",
    "logoUrl": "/src/data/assets/logos/astrazeneca.svg",
    "headerImageUrl": "/images/headers/astrazeneca-header.jpg",
    "headquarters": "Cambridge, United Kingdom",
    "founded": "1999",
    "website": "astrazeneca.com",
    "marketCap": 210.7,
    "employees": 83000,
    "stockSymbol": "AZN",
    "stockExchange": "LSE",
    "therapeuticAreas": [
      "oncology",
      "respiratory",
      "cardiovascular",
      "renal",
      "metabolic",
      "autoimmunity"
    ],
    "products": [
      {
        "id": "respiclear",
        "name": "RespiClear",
        "description": "Next-generation inhaled therapy for severe asthma and COPD.",
        "status": "marketed",
        "approvalDate": "2019-11-10",
        "therapeuticAreas": ["respiratory"]
      },
      {
        "id": "cardiostat",
        "name": "CardioStat",
        "description": "Novel anti-thrombotic medication for cardiovascular events prevention.",
        "status": "phase3",
        "therapeuticAreas": ["cardiovascular"]
      }
    ],
    "relatedCompanies": [
      {
        "id": "pfizer",
        "relationship": "competitor"
      },
      {
        "id": "novartis",
        "relationship": "partner"
      }
    ],
    "milestones": [
      {
        "date": "2020-12-30",
        "title": "COVID-19 Vaccine Approval",
        "description": "Received UK approval for COVID-19 vaccine developed with Oxford University.",
        "type": "regulatory"
      },
      {
        "date": "2019-03-19",
        "title": "Biopharmaceuticals R&D Reorganization",
        "description": "Announced reorganization of R&D and creation of separate oncology unit.",
        "type": "merger"
      },
      {
        "date": "2015-07-31",
        "title": "ZS Pharma Acquisition",
        "description": "Acquired ZS Pharma for $2.7 billion, expanding cardiovascular and metabolic portfolio.",
        "type": "acquisition"
      }
    ],
    "financials": [
      {
        "year": 2023,
        "revenue": 45.8,
        "rAndDSpending": 9.5,
        "netIncome": 6.9
      },
      {
        "year": 2022,
        "revenue": 44.4,
        "rAndDSpending": 9.0,
        "netIncome": 5.8
      },
      {
        "year": 2021,
        "revenue": 37.4,
        "rAndDSpending": 8.0,
        "netIncome": 0.6
      },
      {
        "year": 2020,
        "revenue": 26.6,
        "rAndDSpending": 6.0,
        "netIncome": 3.2
      },
      {
        "year": 2019,
        "revenue": 24.4,
        "rAndDSpending": 5.3,
        "netIncome": 1.3
      }
    ]
  }
]